Weiss Ratings Reaffirms Hold (C) Rating for HUTCHMED (NASDAQ:HCM)

HUTCHMED (NASDAQ:HCM - Get Free Report)'s stock had its "hold (c)" rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other equities analysts have also recently issued reports on HCM. Bank of America increased their target price on HUTCHMED from $27.00 to $28.00 and gave the stock a "buy" rating in a report on Tuesday, July 22nd. Morgan Stanley downgraded shares of HUTCHMED from an "equal weight" rating to an "underweight" rating and reduced their target price for the company from $18.00 to $13.75 in a research note on Monday, September 22nd. Wall Street Zen downgraded shares of HUTCHMED from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Finally, Zacks Research downgraded shares of HUTCHMED from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 9th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $20.88.

HUTCHMED Price Performance

Shares of HUTCHMED stock opened at $16.39 on Wednesday. The company has a current ratio of 4.65, a quick ratio of 4.51 and a debt-to-equity ratio of 0.05. The firm's 50-day simple moving average is $16.19 and its 200-day simple moving average is $15.47. HUTCHMED has a twelve month low of $11.51 and a twelve month high of $21.50.

Institutional Investors Weigh In On HUTCHMED

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Crossmark Global Holdings Inc. increased its position in HUTCHMED by 31.4% in the 1st quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company's stock valued at $367,000 after acquiring an additional 5,829 shares in the last quarter. Bank of America Corp DE grew its stake in shares of HUTCHMED by 40.4% during the fourth quarter. Bank of America Corp DE now owns 22,723 shares of the company's stock valued at $327,000 after purchasing an additional 6,540 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in HUTCHMED by 8.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company's stock worth $1,413,000 after buying an additional 7,342 shares in the last quarter. Vident Advisory LLC lifted its holdings in HUTCHMED by 78.3% during the 1st quarter. Vident Advisory LLC now owns 19,728 shares of the company's stock worth $297,000 after buying an additional 8,664 shares in the last quarter. Finally, XY Capital Ltd lifted its holdings in HUTCHMED by 142.4% during the 1st quarter. XY Capital Ltd now owns 113,136 shares of the company's stock worth $1,702,000 after buying an additional 66,460 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company's stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.